Logo image of LLY

ELI LILLY & CO (LLY) Stock Price, Quote, News and Overview

NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD

747.01  -8.1 (-1.07%)

After market: 747.01 0 (0%)

LLY Quote, Performance and Key Statistics

ELI LILLY & CO

NYSE:LLY (5/20/2025, 9:35:42 PM)

After market: 747.01 0 (0%)

747.01

-8.1 (-1.07%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High972.53
52 Week Low677.09
Market Cap708.16B
Shares947.99M
Float945.87M
Yearly Dividend4.93
Dividend Yield0.82%
PE54.29
Fwd PE24.97
Earnings (Next)08-07 2025-08-07/bmo
IPO07-09 1970-07-09


LLY short term performance overview.The bars show the price performance of LLY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10

LLY long term performance overview.The bars show the price performance of LLY in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of LLY is 747.01 USD. In the past month the price decreased by -9.73%. In the past year, price decreased by -7.48%.

ELI LILLY & CO / LLY Daily stock chart

LLY Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
JNJ JOHNSON & JOHNSON 15.29 369.72B
NVO NOVO-NORDISK A/S-SPONS ADR 19.6 302.74B
NVS NOVARTIS AG-SPONSORED ADR 13.51 221.76B
AZN ASTRAZENECA PLC-SPONS ADR 18.8 216.78B
MRK MERCK & CO. INC. 10.01 196.20B
PFE PFIZER INC 7.33 133.39B
SNY SANOFI-ADR 13.85 129.48B
BMY BRISTOL-MYERS SQUIBB CO 6.52 97.42B
GSK GSK PLC-SPON ADR 6.99 77.70B
ZTS ZOETIS INC 27.18 73.00B
HLN HALEON PLC-ADR 22.49 49.69B
TAK TAKEDA PHARMACEUTIC-SP ADR 26.43 44.91B

About LLY

Company Profile

LLY logo image Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). The company also owns a lead therapeutic molecule FXR314.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094

Indianapolis INDIANA 46285 US

CEO: David A. Ricks

Employees: 47000

LLY Company Website

LLY Investor Relations

Phone: 13172762000

ELI LILLY & CO / LLY FAQ

What is the stock price of ELI LILLY & CO today?

The current stock price of LLY is 747.01 USD. The price decreased by -1.07% in the last trading session.


What is the ticker symbol for ELI LILLY & CO stock?

The exchange symbol of ELI LILLY & CO is LLY and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is LLY stock listed?

LLY stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for ELI LILLY & CO stock?

33 analysts have analysed LLY and the average price target is 1013.54 USD. This implies a price increase of 35.68% is expected in the next year compared to the current price of 747.01. Check the ELI LILLY & CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ELI LILLY & CO worth?

ELI LILLY & CO (LLY) has a market capitalization of 708.16B USD. This makes LLY a Mega Cap stock.


How many employees does ELI LILLY & CO have?

ELI LILLY & CO (LLY) currently has 47000 employees.


What are the support and resistance levels for ELI LILLY & CO (LLY) stock?

ELI LILLY & CO (LLY) has a support level at 746.71 and a resistance level at 747.27. Check the full technical report for a detailed analysis of LLY support and resistance levels.


Is ELI LILLY & CO (LLY) expected to grow?

The Revenue of ELI LILLY & CO (LLY) is expected to grow by 31.67% in the next year. Check the estimates tab for more information on the LLY EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ELI LILLY & CO (LLY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ELI LILLY & CO (LLY) stock pay dividends?

ELI LILLY & CO (LLY) has a dividend yield of 0.82%. The yearly dividend amount is currently 4.93. Check the full fundamental report for a detailed analysis of LLY dividend history, reliability and sustainability.


When does ELI LILLY & CO (LLY) report earnings?

ELI LILLY & CO (LLY) will report earnings on 2025-08-07, before the market open.


What is the Price/Earnings (PE) ratio of ELI LILLY & CO (LLY)?

The PE ratio for ELI LILLY & CO (LLY) is 54.29. This is based on the reported non-GAAP earnings per share of 13.76 and the current share price of 747.01 USD. Check the full fundamental report for a full analysis of the valuation metrics for LLY.


What is the Short Interest ratio of ELI LILLY & CO (LLY) stock?

The outstanding short interest for ELI LILLY & CO (LLY) is 0.78% of its float. Check the ownership tab for more information on the LLY short interest.


LLY Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LLY Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to LLY. LLY scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LLY Financial Highlights

Over the last trailing twelve months LLY reported a non-GAAP Earnings per Share(EPS) of 13.76. The EPS increased by 89.01% compared to the year before.


Industry RankSector Rank
PM (TTM) 22.66%
ROA 12.42%
ROE 70.45%
Debt/Equity 2.19
Chartmill High Growth Momentum
EPS Q2Q%29.46%
Sales Q2Q%45.17%
EPS 1Y (TTM)89.01%
Revenue 1Y (TTM)36.38%

LLY Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 81% to LLY. The Buy consensus is the average rating of analysts ratings from 33 analysts.

For the next year, analysts expect an EPS growth of 68% and a revenue growth 31.67% for LLY


Ownership
Inst Owners83.27%
Ins Owners0.16%
Short Float %0.78%
Short Ratio1.76
Analysts
Analysts81.21
Price Target1013.54 (35.68%)
EPS Next Y68%
Revenue Next Year31.67%